TJC0133 is an NCE compound of second-generation TLR4 antagonist, which is somewhat different in mechanism of action (MOA) than the first-generation antagonist. TJC0133 showed better TLR4 inhibition activity and efficacy in many animal disease models, including NASH, IPF, and IBD. More other disease models for indication patent application strategy are under development process.